55,342 Shares in Pharvaris N.V. $PHVS Acquired by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP bought a new position in shares of Pharvaris N.V. (NASDAQ:PHVS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 55,342 shares of the company’s stock, valued at approximately $1,536,000. Pharvaris comprises about 1.2% of Seven Fleet Capital Management LP’s portfolio, making the stock its 12th biggest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PHVS. General Atlantic L.P. raised its stake in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC increased its holdings in Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after purchasing an additional 368,000 shares during the period. venBio Partners LLC increased its holdings in Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. raised its position in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP raised its position in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the last quarter.

Pharvaris Stock Down 1.8%

PHVS stock opened at $32.80 on Friday. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -10.31 and a beta of -2.35. Pharvaris N.V. has a 12-month low of $16.72 and a 12-month high of $34.41. The company’s fifty day simple moving average is $29.91 and its 200 day simple moving average is $27.71.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Research analysts expect that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 23,333 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the sale, the chief executive officer owned 142,084 shares of the company’s stock, valued at $3,941,410.16. This trade represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Anne Lesage sold 21,700 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.26, for a total value of $656,642.00. Following the completion of the sale, the insider owned 56,450 shares of the company’s stock, valued at approximately $1,708,177. The trade was a 27.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 214,909 shares of company stock worth $6,421,745 over the last three months. Insiders own 11.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wedbush upped their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citizens Jmp cut their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Royal Bank Of Canada reduced their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.